Senescent cell clearance as neurodegeneration therapy

RESOLVED

Investigate the therapeutic potential of clearing senescent cells (senolytics) to slow or reverse neurodegeneration. Key questions: 1. Which senescent cell types in the brain contribute most to neurodegeneration (microglia, astrocytes, oligodendrocyte precursors)? 2. What senolytic compounds (dasatinib+quercetin, navitoclax, fisetin) show BBB penetration and CNS efficacy? 3. What is the evidence from animal models linking cellular senescence to Alzheimer's, Parkinson's, and other neurodegenerative diseases? 4. What are the risks of removing senescent cells in the aging brain (e.g., loss of SASP-mediated repair signals)? 5. What clinical trials exist or are planned for senolytics in neurodegeneration?

Priority: 0.95 Domain: neurodegeneration Hypotheses: 5

📊 Landscape Analysis

Landscape Summary: Senescent cell clearance as neurodegeneration therapy is a 0.95 priority gap in neurodegeneration. It has 5 linked hypotheses with average composite score 0.000. Status: resolved.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Senescent cell clearance as neurodegeneration therapy — INVOKE-2 (completed)

📈 Living Dashboards

Hypotheses

0.000

Top Score

0.000

Avg Score

Debates

0.95

Avg Quality

100%

Resolution

Mechanistic Families

Gap Resolution Progress100%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

Oligodendrocyte Precursor Cell Senescence as Primary Driver of White M

Target: BCL2L1, SOX10, PDGFRA Pathway: N/A

0.000

score

Apolipoprotein E-Mediated Senescent Cell Targeting System

Target: APOE, LRP1, CDKN1A Pathway: N/A

0.000

score

Selective Microglial Senescence Targeting via P16INK4A-Guided Senolyti

Target: CDKN2A, BCL2L1, BCL2 Pathway: N/A

0.000

score

Temporal SASP Modulation Rather Than Complete Senolytic Clearance

Target: MTOR, RELA, NLRP3 Pathway: N/A

0.000

score

Senescence-Induced Tau Propagation Blockade

Target: MAPT, CDKN2A, BCL-2 family Pathway: N/A

0.000

score

Fisetin-Based Senomorphic Therapy for Preserving Beneficial Senescent

Target: SIRT1, FOXO3, GFAP Pathway: N/A

0.000

score

Circadian-Synchronized Senolytic Delivery

Target: CLOCK, ARNTL, ATG5 Pathway: N/A

0.000

score

🌊 Knowledge Graph Connections

No knowledge graph edges recorded

🕑 Activity Feed

📈 Oligodendrocyte Precursor Cell Senescence as Primary Driver score=0.000 2026-04-28T21:13

📈 Apolipoprotein E-Mediated Senescent Cell Targeting System score=0.000 2026-04-28T21:13

📈 Selective Microglial Senescence Targeting via P16INK4A-Guide score=0.000 2026-04-28T21:13

📈 Temporal SASP Modulation Rather Than Complete Senolytic Clea score=0.000 2026-04-28T21:13

📈 Senescence-Induced Tau Propagation Blockade score=0.000 2026-04-28T21:13

🎭 Senescent cell clearance as neurodegeneration therapy q=0.95 2026-04-04T04:51

🎭 Senescent cell clearance as neurodegeneration therapy q=0.95 2026-04-02T06:43

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps